MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
Hong Kong hospitality: Momentum and the new lifestyle era
Understanding Hong Kong’s new land premium policy
Hong Kong: At the forefront of digitalisation and evolving international disputes
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings
Capital repatriation isn't a retreat — it’s Hong Kong’s regulatory graduation